Evolution of pain at 3 months by oral resveratrol in knee osteoarthritis (ARTHROL): protocol for a multicentre randomised double-blind placebo-controlled trial

Christelle Nguyen, Isabelle Boutron, Gabriel Baron, Emmanuel Coudeyre, Francis Berenbaum, Serge Poiraudeau, François Rannou, Christelle Nguyen, Isabelle Boutron, Gabriel Baron, Emmanuel Coudeyre, Francis Berenbaum, Serge Poiraudeau, François Rannou

Abstract

Introduction: Osteoarthritis (OA) pathophysiology is driven in part by joint inflammation. Resveratrol has in vitro anti-inflammatory properties. We aim to assess the efficacy of oral resveratrol for knee pain at 3 months in people with knee OA.

Methods and analysis: We will conduct a randomised double-blind placebo-controlled trial. Overall, 164 individuals with knee OA fulfilling 1986 American College of Rheumatology criteria will be recruited in three tertiary care centres in France and randomised to receive oral resveratrol, 40 mg (two caplets) two times per day for 1 week, then 20 mg (one caplet) two times per day or a matching placebo for a total of 6 months. Randomisation will be centralised and stratified by centre. The allocation ratio of assignments will be 1:1. The primary outcome will be the mean change from baseline in knee pain on a self-administered 11-point pain Numeric Rating Scale at 3 months. Secondary outcomes will be the mean change in knee pain at 6 months, the function subscore of the Western Ontario and McMaster Universities Arthritis Index score, patient global assessment, proportion of responders according to the Osteoarthritis Research Society International-Outcome Measures in Rheumatology criteria at 3 and 6 months, and self-reported number of intra-articular injections of corticosteroids or hyaluronic acid and consumption of analgesics and non-steroidal anti-inflammatory drugs since the last contact. Other interventions will be allowed and self-reported. Adherence will be monitored by capsule counts and a booklet and adverse events recorded at 3 and 6 months. Statisticians, treating physicians and participants will be blinded to the allocated treatment.

Ethics and dissemination: The oral resveratrol in knee osteoarthritis (ARTHROL) trial has been authorised by the AgenceNationale de Sécurité du Médicament et des Produits de Santé and ethics were approved by the Comité deProtection des Personnes Île-de-France III. The findings of the study will be published in a peer-reviewed journal and disseminated at conferences. The design of ARTHROL will warrant the translation of its findings into clinical practice.

Trial registration number: ClinicalTrials.gov identifier: NCT02905799. Pre-results. First received: 14 September 2016. Last updated: 16 September 2016. Status: not yet recruiting.

Keywords: Osteoarthritis; clinical trial.; knee; oral treatment; pain; resveratrol.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. Disease GBD, Injury I, Global PC. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–602. 10.1016/S0140-6736(16)31678-6
    1. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377:2115–26. 10.1016/S0140-6736(11)60243-2
    1. Palazzo C, Ravaud JF, Papelard A, et al. . The burden of musculoskeletal conditions. PLoS One 2014;9:e90633 10.1371/journal.pone.0090633
    1. Richette P, Latourte A, Frazier A. Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend? Expert Opin Drug Saf 2015;14:1259–68. 10.1517/14740338.2015.1056776
    1. Roberts E, Delgado Nunes V, Buckner S, et al. . Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016;75 10.1136/annrheumdis-2014-206914
    1. Vang O, Ahmad N, Baile CA, et al. . What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011;6:e19881 10.1371/journal.pone.0019881
    1. Nguyen C, Savouret JF, Widerak M, et al. . Resveratrol, potential therapeutic interest in joint disorders: a critical narrative Review. Nutrients 2017;9:45 10.3390/nu9010045
    1. Dave M, Attur M, Palmer G, et al. . The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008;58:2786–97. 10.1002/art.23799
    1. Li X, Phillips FM, An HS, et al. . The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc. Spine 2008;33:2586–95. 10.1097/BRS.0b013e3181883883
    1. Malemud CJ. Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr Opin Pharmacol 2007;7:339–43. 10.1016/j.coph.2006.11.012
    1. Mengshol JA, Vincenti MP, Coon CI, et al. . Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000;43:801–11. 10.1002/1529-0131(200004)43:4<801::AID-ANR10>;2-4
    1. Shakibaei M, Mobasheri A, Buhrmann C. Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro. Genes Nutr 2011;6:171–9. 10.1007/s12263-010-0179-5
    1. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 2009;11:R165 10.1186/ar2850
    1. Lei M, Liu SQ, Liu YL. Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1beta. Acta Pharmacol Sin 2008;29:1350–6. 10.1111/j.1745-7254.2008.00880.x
    1. Liu FC, Hung LF, Wu WL, et al. . Chondroprotective effects and mechanisms of resveratrol in advanced glycation end products-stimulated chondrocytes. Arthritis Res Ther 2010;12:R167 10.1186/ar3127
    1. Shakibaei M, Csaki C, Nebrich S, et al. . Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008;76:1426–39. 10.1016/j.bcp.2008.05.029
    1. Tian J, Chen JW, Gao JS, et al. . Resveratrol inhibits TNF-α-induced IL-1β, MMP-3 production in human rheumatoid arthritis fibroblast-like synoviocytes via modulation of PI3kinase/Akt pathway. Rheumatol Int 2013;33:1829–35. 10.1007/s00296-012-2657-0
    1. Byun HS, Song JK, Kim YR, et al. . Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes. Rheumatology 2008;47:301–8. 10.1093/rheumatology/kem368
    1. Ferrero ME, Bertelli AE, Fulgenzi A, et al. . Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 1998;68:1208–14.
    1. Vorderstrasse BA, Steppan LB, Silverstone AE, et al. . Aryl hydrocarbon receptor-deficient mice generate normal immune responses to model antigens and are resistant to TCDD-induced immune suppression. Toxicol Appl Pharmacol 2001;171:157–64. 10.1006/taap.2000.9122
    1. Elmali N, Esenkaya I, Harma A, et al. . Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 2005;54:158–62. 10.1007/s00011-004-1341-6
    1. Wang J, Gao JS, Chen JW, et al. . Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol Int 2012;32:1541–8. 10.1007/s00296-010-1720-y
    1. Li W, Cai L, Zhang Y, et al. . Intra-articular resveratrol injection prevents osteoarthritis progression in a mouse model by activating SIRT1 and thereby silencing HIF-2α. J Orthop Res 2015;33:1061–70. 10.1002/jor.22859
    1. Amiot MJ, Romier B, Dao TM, et al. . Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 2013;95:1233–8. 10.1016/j.biochi.2013.01.008
    1. Schulz KF, Altman DG, Moher D, et al. . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332 10.1136/bmj.c332
    1. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, et al. . Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010;54:7–16. 10.1002/mnfr.200900437
    1. Bellamy N, Kirwan J, Boers M, et al. . Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799–802.
    1. McAlindon TE, Driban JB, Henrotin Y, et al. . OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthritis Cartilage 2015;23:747–60. 10.1016/j.joca.2015.03.005
    1. Bellamy N, Buchanan WW, Goldsmith CH, et al. . Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40.
    1. Pham T, van der Heijde D, Altman RD, et al. . OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389–99. 10.1016/j.joca.2004.02.001

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する